stockrowSotera Health Company
SHC Healthcare Diagnostics & Research
Sotera Health Company’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, up 5.74% from fiscal 2024.
- Revenue
- +4.36%
- EPS
- +20.1%
- Free cash flow
- +65.0%
- Total debt
- +0.14%
Quarter to September 2026, against a year earlier
Follow SHC
Alert me
Sotera Health Company (SHC) EV/FCF
As of 5 November 2026, Sotera Health Company (SHC) trades at a EV/FCF of 47.0×. Over the past ten years it has ranged from −21.6× (July 2023) to 212× (September 2024); the current reading is higher than 32% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | 46.2× | (64.71%) |
| FY2024 | 131× | — |
| FY2023 | −18.3× | — |
| FY2022 | 41.2× | (10.56%) |
| FY2021 | 46.1× | (64.58%) |
| FY2020 | 130× | 134.08% |
| FY2019 | 55.6× | 0.00% |
| FY2018 | 55.6× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2026 | 52.5× | (14.75%) |
| Jun 2026 | 61.6× | (0.53%) |
| Mar 2026 | 62.0× | 34.02% |
| Dec 2025 | 46.2× | (37.47%) |
| 24 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| ADPT Adaptive Biotechnologies Corporation compare | −494× |
| NEO NeoGenomics, Inc. compare | −96.9× |
| GRAL GRAIL, Inc. compare | −15.9× |
| VCYT Veracyte, Inc. compare | 9.0× |
| QGEN QIAGEN N.V. compare | 25.8× |
| SHC Sotera Health Company | 47.0× |
| CDNA CareDx, Inc. compare | 64.7× |
| BLLN BillionToOne, Inc. compare | 142× |
| RDNT RadNet, Inc. compare | 208× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on SHC
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement